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Abstract
Background: Higher latitude and human leukocyte antigen (HLA)-DRB1*04:05 increase susceptibility to multiple
sclerosis (MS) in the Japanese population, but their effects on disease severity are unknown. We aimed to clarify the
effects of latitude and the HLA-DRB1 and HLA-DPB1 genes on disease severity in Japanese patients with MS.
Methods: We enrolled 247 MS patients and 159 healthy controls (HCs) from the northernmost main island of
Japan, Hokkaido Island (42–45° north), and 187 MS patients and 235 HCs from the southern half (33–35° north) of
the Japanese archipelago (33–45° north). We genotyped HLA-DRB1 and HLA-DPB1 alleles, compared demographic
features, and analyzed factors contributing to differences in clinical and laboratory findings between MS patients
from southern and northern Japan. The Multiple Sclerosis Severity Score (MSSS), which adjusts the Kurtzke’s
Expanded Disability Status Scale score according to disease duration, was used to estimate disease severity.
Results: The HLA-DRB1*04:05 and DRB1*15:01 alleles conferred susceptibility to MS in our Japanese population
(pcorr = 0.0004 and pcorr = 0.0019, respectively). Southern patients had higher MSSS scores than northern
patients (p = 0.003). Northern patients had higher frequencies of brain lesions meeting the Barkhof criteria
(Barkhof brain lesions) and cerebrospinal fluid (CSF) IgG abnormalities than southern patients (p = 0.0012 and
p < 0.0001, respectively). DRB1*04:05-positive MS patients had lower MSSS scores and lower frequencies of
Barkhof brain lesions and CSF IgG abnormalities than DRB1*04:05-negative MS patients (p = 0.0415, p = 0.0026,
and p < 0.0001, respectively). Multivariate analyses revealed that latitude and DRB1*04:05 were independently
associated with the lowest quartile of MSSS and that latitude was positively associated with Barkhof brain
lesions and CSF IgG abnormalities. DRB1*04:05 was negatively associated with these parameters. MSSS was
decreased by 0.57 per DRB1*04:05 allele (p = 0.0198).
Conclusions: Living at a higher latitude and carrying the DRB1*04:05 allele independently lessens MS symptom
severity as defined by MSSS. However, these factors influence the frequency of Barkhof brain lesions and CSF IgG
abnormalities in opposite ways; higher latitude increases the frequency of Barkhof brain lesions and CSF IgG
abnormalities, whereas DRB1*04:05 decreases them.
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Background
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system characterized by inflammation, de-
myelination, and axonal injury [1]. MS susceptibility and
phenotypes result from complex interactions between
multiple genetic and environmental factors [2]. It is well
established that the class II subregion of the human
leukocyte antigen (HLA) gene on chromosome 6p21
plays the most important role in determining MS
susceptibility [3]. The DR15 haplotype (DRB1*15:01-
DQA1*01:02-DQB1*06:02) is strongly associated with
MS, and the effect is mainly driven by HLA-DRB1*15:01
in people of northern European descent [4, 5]. Although
DRB1 alleles clearly influence MS susceptibility, it is not
known how HLA variation influences the clinical fea-
tures of MS, especially in Asian populations.
We previously reported that the HLA-DRB1*04:05 allele
is the strongest genetic risk factor for MS in the southern
Japanese population. The clinical phenotypes of patients
with the HLA-DRB1*04:05 allele include a milder clinical
course, younger age at disease onset, slower disease pro-
gression, fewer brain lesions, and rare cerebrospinal fluid
(CSF) IgG abnormalities compared with patients lacking
the HLA-DRB1*04:05 allele [6]. It is widely known that
the risk for MS increases with distance from the equator
[7], suggesting that environmental risk factors related to
latitude, such as decreased sunlight exposure and vitamin
D levels, are involved [8]. Additionally, despite genetic
homogeneity, there are phenotypic differences between
northern and southern Japanese patients with MS. In the
fourth nationwide survey in Japan, brain magnetic reson-
ance imaging (MRI) findings fulfilling the Barkhof criteria
[9] were significantly more common in northern patients
than in southern patients and more frequent in northern-
born northern residents than northern-born southern res-
idents [10]. Recent studies in Western countries have
revealed an association between latitude and the presence
of oligoclonal IgG bands (OB) or increased intrathecal
production of IgG [11, 12]. We have also reported that
latitude independently affects the emergence of CSF IgG
abnormalities in Japanese patients with MS [13].
These observations suggest that latitude may influence
the clinical phenotype of MS. However, the relationship
between latitude and disease severity still remains un-
clear. Thus, the aim of this study was to clarify the
influence of latitude and HLA-DRB1 on disease severity
in Japanese patients withMS.
Methods
Participants
Patients with MS, agreeing to participate in this study,
were recruited from nine institutes in Japan. MS was di-
agnosed using the 2010 revised McDonald criteria [14].
Patients with neuromyelitis optica [15], neuromyelitis
optica spectrum disorders [16], or longitudinally exten-
sive spinal cord lesions extending over three or more
vertebral segments were excluded. Patients with primary
progressive MS (PPMS) were also excluded because of
the low prevalence of PPMS in the Japanese population
[10], as well as the association between PPMS and dis-
tinct HLA class II alleles from relapse-onset MS [17, 18].
Participants were recruited from the northern and
southern parts of the Japanese archipelago, which spans
33–45° north (Additional file 1: Figure S1). Patients re-
cruited from Hokkaido Island, the northernmost main
island of Japan (42–45° north), were classified as the
northern group, and those recruited from the southern
half of the Japanese archipelago (33–35° north) were
classed as the southern group. Patients residing on
Hokkaido were chosen for the northern group because
most people living on Hokkaido are descendants of
immigrants who came from the other main islands 100–
150 years ago, during the Meiji era, and thus share simi-
lar genetic makeup with modern inhabitants of the other
main islands [10]. These populations were considered
suitable for studying the effects of latitude, because of
the latitude difference of at least 7° between Hokkaido
Island and southern Japan. In total, 247 patients with
MS and 159 healthy controls (HCs) in the northern
group, and 187 patients with MS and 235 HCs in the
southern group, participated in this study. Although sex
and age were not matched between MS patients and
HCs, HCs were used only for comparing HLA pheno-
typic frequency. Therefore, we believe that the use of
unmatched HCs would not distort our results. We col-
lected the demographic and clinical data of the partici-
pants including sex, age, age at disease onset, disease
duration, MS subtype, annualized relapse rate (ARR),
Kurtzke’s Expanded Disability Status Scale (EDSS) [19]
score, and Multiple Sclerosis Severity Score (MSSS) [20]
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at the time of DNA blood sampling. Fulfillment of the
Barkhof criteria for MS [9], positivity of CSF OB (deter-
mined by isoelectric focusing) [21], and abnormality of
IgG index as calculated by (CSF IgG/serum IgG)/(CSF
albumin/serum albumin) were determined by retrospect-
ive review of each participant’s medical records. In all
patients, the presence of OB in CSF was assessed in a
single laboratory (LSI Medience Corporation, Tokyo,
Japan) and EDSS scores measured during remission were
used. MSSS, which adjusts the EDSS score according to
disease duration, was used to estimate the disease sever-
ity for each individual patient on a cross-sectional basis
[20]. We defined the presence of Barkhof brain lesions
by fulfillment of the four dichotomized MRI parameters
proposed by Barkhof et al.: (1) the presence of at least
one gadolinium-enhancing lesion or nine T2 hyperin-
tense lesions, (2) the presence of at least one infratentor-
ial lesion, (3) the presence of at least one juxtacortical
lesion, and (4) the presence of at least three
periventricular lesions [9]. We included cerebellar le-
sions as infratentorial lesions in the criteria. The IgG
index was considered to be elevated if it was >0.658 [22].
We defined secondary progressive MS (SPMS) as a sus-
tained increase in ≥1 point when EDSS was ≤5.5 and as
a sustained increase in EDSS of ≥0.5 point when EDSS
was ≥6.0 [23]. Benign MS was defined by an EDSS score
of ≤2.0 at least 10 years after disease onset [24]. Patients
and HCs were recruited from June 2012 to January 2013
in the northern group and from April 2006 to January
2013 in the southern group [6]. As the prevalence of MS
is lower in southern Japan than in northern Japan [25], a
longer recruitment period was allowed in the southern
group. The sample sizes required to reveal an association
of the HLA-DRB1*04:05 allele with MS were calculated
to be 122 cases and 122 controls, based on our previous
report [6]. We also collected clinical data from 109 of
the 187 southern patients up to January 2013 to adjust
for the different recruitment periods between the
groups. The ethics committees of each institution ap-
proved this study, and written informed consent was ob-
tained from all participants.
HLA-DRB1 and HLA-DPB1 genotyping
The genotypes of the participants HLA-DRB1 and HLA-
DPB1 alleles were determined by hybridization between
polymerase chain reaction amplification products of the
HLA-DRB1 and HLA-DPB1 genes and sequence-specific
oligonucleotide probes, as previously described [26].
Statistical analysis
The phenotypic frequencies of the HLA-DRB1 and
HLA-DPB1 alleles were compared using either the
chi-square test or Fisher’s exact probability test (when
criteria for the chi-square test were not fulfilled). The
chi-square test was used to compare sex, SPMS, brain
MRI lesions meeting the Barkhof criteria, and CSF
IgG abnormalities between subgroups. We performed
the Shapiro–Wilk test for normality for continuous
variables, such as age, age at onset, disease duration,
ARR, EDSS, and MSSS. As these continuous variables
were not normally distributed, we used the Mann–
Whitney U test for comparisons between subgroups.
The Mann–Whitney U test was also used to compare
MSSS between patients with and without Barkhof
brain lesions and between patients with and without
CSF IgG abnormalities.
A multivariate linear regression model was used for
continuous dependent variables (log-transformed age
at onset), while a logistic regression model was used
for binary dependent variables (benign MS, fulfillment
of Barkhof criteria for MS, and CSF IgG abnormal-
ities), adjusting for other factors associated with
dependent variables. We divided MSSS into quartiles
defined by MSSS values of 0.94, 2.60, and 5.50, and a
logistic regression model was used. All analyses were
performed using JMP 11.0.0 (SAS Institute Inc., Cary,
NC, USA). Statistical significance was set at p < 0.05.
Uncorrected p values (puncorr) were corrected by
multiplying them by the number of comparisons




The clinical features of the 434 patients with MS (314
females, 120 males) are summarized in Table 1. The me-
dian age at disease onset was 29 years (interquartile
range 22–38 years). The frequency of SPMS was 17.1 %.
The median EDSS score was 2.0 (interquartile range
1.0–3.5), and the median MSSS was 2.60 (interquartile
range 0.94–5.50). A total of 318 patients (74.3 %) had
Barkhof brain lesions, and 193 patients (58.7 %) had CSF
IgG abnormalities.
Frequencies of the HLA-DRB1 and HLA-DPB1 alleles
As shown in Table 2, the phenotypic frequencies of the
DRB1*04:05 and DRB1*15:01 alleles were significantly
higher in MS patients than HCs (pcorr = 0.0004 and pcorr =
0.0019, respectively). The phenotypic frequencies of
DRB1*01:01, DRB1*09:01, DRB1*13:02, and DRB1*15:02
were significantly lower in MS patients than HCs (pcorr =
0.003, pcorr = 0.0198, pcorr = 0.0066, and pcorr = 0.0396, re-
spectively). No DPB1 alleles were associated with MS in
Japan (Additional file 2: Table S1). Compared with HCs,
the phenotype frequency of DRB1*04:05 was significantly
higher in patients with MS in both northern and southern
regions (pcorr = 0.0224 and pcorr = 0.0384, respectively)
(Additional file 2: Tables S2 and S3). There was no
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significant difference in the distribution of DRB1 alleles
between northern and southern HCs (Additional file 2:
Table S4).
Comparison of clinical characteristics between northern
and southern patients
Northern MS patients had significantly lower MSSS
scores compared with southern patients (p = 0.003)
(Table 1), although the frequency of SPMS was higher in
the north than in the south (p = 0.0039). Northern pa-
tients had a significantly longer disease duration, a higher
frequency of Barkhof brain lesions, and a higher
frequency of CSF IgG abnormalities compared with
southern patients (p < 0.0001, p = 0.0012, and p < 0.0001,
respectively). Even after excluding all SPMS patients,
northern patients had a significantly longer disease dur-
ation, lower EDSS and MSSS, and higher frequencies of
Barkhof brain lesions and CSF IgG abnormalities com-
pared with southern patients (p = 0.0004, p = 0.0008, p <
0.0001, p = 0.0217, and p < 0.0001, respectively) (Add-
itional file 2: Table S5). Similar results were seen when
comparing MS patients between northern and southern
Japan. There were no significant differences in the pheno-
typic frequencies of HLA-DRB1 04:05 and HLA-DRB1
15:01 between northern and southern patients (37.3 vs.
42.8 %, p = 0.2432; 30.4 vs. 26.7 %, p = 0.4087, respect-
ively) (Table 1). After excluding all SPMS patients, there
were still no differences in the frequencies of either allele
between northern and southern patients (HLA-DRB1
04:05, 37.6 vs. 43.7 %, p = 0.2403; HLA-DRB1 15:01, 30.9
vs. 27.5 %, p = 0.4816) (Additional file 2: Table S5).
When we compared the demographic features of
northern and southern patients with using clinical data
from southern patients that were followed up until
January 2013, there were no significant differences in
disease duration, EDSS, or MSSS, although SPMS fre-
quency was significantly higher in northern Japan (p =
0.0256) (Additional file 2: Table S6). When we excluded
SPMS patients from the MS patient group, to adjust for
the different recruitment periods, the northern patients
had significantly lower MSSS (median 1.45 vs. 2.23, p =
0.0411) (Additional file 2: Table S7).
We examined the association of MSSS with Barkhof
brain lesions and CSF IgG abnormalities and found that
neither was associated with MSSS in the total population
nor in the northern or southern MS patient populations
(Additional file 2: Table S8).
Comparison of clinical characteristics between
HLA-DRB1*04:05-positive and HLA-DRB1*04:05-negative
patients
MS patients with DRB1*04:05 were younger at disease on-
set, had a lower MSSS score, and had lower frequencies of
Barkhof brain lesions and CSF IgG abnormalities than
those without DRB1*04:05 (p = 0.0003, p = 0.0415, p =
0.0026, and p < 0.0001, respectively) (Table 3). In southern
MS patients, DRB1*04:05 carriers were younger and had an
earlier onset, longer disease duration, lower EDSS and
MSSS scores, and lower frequencies of Barkhof brain le-
sions and CSF IgG abnormalities than non-DRB1*04:05
carriers (p = 0.0334, p = 0.0001, p = 0.0133, p = 0.0263, p =
0.0021, p = 0.0143, and p = 0.008, respectively). In northern
patients, DRB1*04:05 carriers also had a lower frequency of
CSF IgG abnormalities than non-DRB1*04:05 carriers (p =
0.0007), while age at onset, MSSS, and Barkhof brain lesion
frequency in northern patients showed similar trends to the
southern patients, but were not significantly different be-
tween DRB1*04:05 carriers and non-DRB1*04:05 carriers.
Table 1 Demographic features of patients with MS according to region
Total patients (n = 434) Northern patients (n = 247) Southern patients (n = 187) p value
Number of males/females (ratio) 120/314 (1:2.6) 62/185 (1:3.0) 58/129 (1:2.2) NS
Age (years)a 41 (33–50) 41 (34–50) 40 (32–50) NS
Age at onset (years)a 29 (22–38) 29 (22–36) 30 (23–40) NS
SPMS (%) 73/427 (17.1) 53/245 (21.6) 20/182 (11.0) 0.0039
Disease duration (years)a 9 (4–15) 10 (6–17) 6.5 (3–13) <0.0001
EDSSa 2.0 (1.0–3.5) 2.0 (1.0–3.5) 2.0 (1.0–3.5) NS
MSSSa 2.60 (0.94–5.50) 2.13 (0.69–5.24) 3.54 (1.45–5.90) 0.003
ARRa 0.41 (0.22–0.75) 0.41 (0.24–0.73) 0.40 (0.20–0.89) NS
Barkhof criteria (%) 318/428 (74.3) 198/247 (80.2) 120/181 (66.3) 0.0012
Positive OB and/or increased IgG index (%) 193/329 (58.7) 130/177 (73.5) 63/152 (41.5) <0.0001
Phenotypic frequency of HLA-DRB1*04:05 (%) 172 (39.6) 92 (37.3) 80 (42.8) NS
Phenotypic frequency of HLA-DRB1*15:01 (%) 125 (28.8) 75 (30.4) 50 (26.7) NS
The Mann–Whitney U test was used to compare continuous variables, and the chi-square test was used to compare categorical variables
ARR annualized relapse rate, EDSS Kurtzke’s Expanded Disability Status Scale, MSSS Multiple Sclerosis Severity Score, NS not significant, OB oligoclonal IgG bands,
SPMS secondary progressive multiple sclerosis
aMedian (interquartile range)
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Comparison of clinical characteristics between
HLA-DRB1*15:01-positive and HLA-DRB1*15:01-negative
patients
HLA-DRB1*15:01 carriers had a significantly higher fre-
quency of CSF IgG abnormalities than non-DRB1*15:01
carriers (p = 0.0058, Additional file 2: Table S9). The effect
of DRB1*15:01 on CSF IgG abnormalities was significant in
southern patients, but not in northern patients (p = 0.0002
and p = 0.9042, respectively).
Comparison of clinical characteristics of HLA-DRB1*04:05- or
HLA-DRB1*15:01-positive patients between northern and
southern Japanese populations
We compared the clinical features of MS patients with
the HLA-DRB1*04:05 or HLA-DRB1*15:01 allele be-
tween northern and southern Japan, respectively (Table 4
and Additional file 2: Table S10). MS patients with
DRB1*04:05 in northern Japan showed higher frequen-
cies of Barkhof brain lesions and positive CSF IgG
Table 2 Phenotypic frequencies of HLA-DRB1 alleles in patients with MS
DRB1 Phenotype frequency, n (%) OR 95 % CI puncorr pcorr
MS (n = 434) HCs (n = 394)
01:01 24 (5.5) 53 (13.5) 0.38 0.23–0.62 <0.0001 0.003
03:03 1 (0.2) 0 NA NA 1.0000 NS
04:01 7 (1.6) 9 (2.3) 0.70 0.26–1.90 0.6151 NS
04:03 42 (9.7) 22 (5.6) 1.81 1.06–3.09 0.0276 NS
04:04 2 (0.5) 2 (0.5) 0.91 0.13–6.47 1.0000 NS
04:05 172 (39.6) 100 (25.4) 1.93 1.43–2.60 <0.0001 0.0004
04:06 42 (9.7) 26 (6.6) 1.52 0.91–2.52 0.1071 NS
04:07 2 (0.5) 4 (1.0) 0.45 0.08–2.48 0.4317 NS
04:10 24 (5.5) 8 (2.0) 2.82 1.25–6.36 0.0091 NS
07:01 1 (0.2) 2 (0.5) 0.45 0.04–5.01 0.6073 NS
07:10 1 (0.2) 0 NA NA 1.0000 NS
08:01 1 (0.2) 1 (0.3) 0.91 0.06–14.56 1.0000 NS
08:02 38 (8.8) 29 (7.4) 1.21 0.73–2.00 0.4622 NS
08:03 63 (14.5) 56 (14.2) 1.02 0.69–1.51 0.9012 NS
09:01 72 (16.6) 104 (26.4) 0.55 0.40–0.78 0.0006 0.0198
10:01 2 (0.5) 2 (0.5) 0.91 0.13–6.47 1.0000 NS
11:01 18 (4.2) 19 (4.8) 0.85 0.44–1.65 0.6388 NS
12:01 26 (6.0) 38 (9.6) 0.60 0.36–1.00 0.0493 NS
12:02 5 (1.2) 15 (3.8) 0.29 0.11–0.82 0.0211 NS
13:01 3 (0.7) 2 (0.5) 1.36 0.23–8.21 1.0000 NS
13:02 20 (4.6) 46 (11.7) 0.37 0.21–0.63 0.0002 0.0066
13:07 0 1 (0.3) 0 NA 0.4758 NS
14:01 3 (0.7) 0 NA NA 0.2508 NS
14:02 1 (0.2) 1 (0.3) 0.91 0.06–14.56 1.0000 NS
14:03 20 (4.6) 14 (3.6) 1.31 0.65–2.63 0.4449 NS
14:05 17 (3.9) 15 (3.8) 1.03 0.51–2.09 0.9347 NS
14:06 11 (2.5) 6 (1.5) 1.68 1.62–4.59 0.3371 NS
14:07 0 2 (0.5) 0 NA 0.2261 NS
14:54 20 (4.6) 28 (7.1) 0.63 0.35–1.14 0.1245 NS
15:01 125 (28.8) 67 (17.0) 1.97 1.41–2.76 <0.0001 0.0019
15:02 55 (12.7) 83 (21.1) 0.54 0.37–0.79 0.0012 0.0396
15:10 1 (0.2) 0 NA NA 1.0000 NS
16:02 4 (0.9) 4 (1.0) 0.91 0.23–3.65 1.0000 NS
puncorr was corrected by multiplying the value by 33 to calculate pcorr
CI confidence interval, HCs healthy controls, MS multiple sclerosis, NA not applicable, NS not significant, OR odds ratio, pcorr corrected p value
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Table 3 Comparison of the clinical features of patients with MS according to the presence or absence of HLA-DRB1*04:05
DRB1 Total patients Northern patients Southern patients
04:05 (+) (n = 172) 04:05 (−) (n = 262) p value 04:05 (+) (n = 92) 04:05 (−) (n = 155) p value 04:05 (+) (n = 80) 04:05 (−) (n = 107) p value
Number of males/females (ratio) 52/120 (1:2.3) 68/194 (1:2.9) NS 27/65 (1:2.4) 35/120 (1:3.4) NS 25/55 (1:2.2) 33/74 (1:2.2) NS
Age (years)a 39 (31–49) 42 (34.2–51.5) 0.0259 41 (34–49.5) 42 (35–51) NS 36 (28–49) 42 (34–52) 0.0334
Age at onset (years)a 26 (21–34.8) 30.2 (24–40) 0.0003 27 (21–34) 29 (24–37) NS 25 (20–36.8) 33 (26–43) 0.0001
SPMS (%) 26/170 (15.3) 47/257 (18.3) NS 19/92 (20.7) 34/153 (22.2) NS 7/78 (9.0) 13/104 (12.5) NS
Disease duration (years)a 9 (5.3–16) 9 (4–14) NS 10 (6–17) 11 (5–17) NS 7.5 (4–14.8) 5.5 (3–10.3) 0.0133
EDSSa 2.0 (1.0–3.5) 2.0 (1.0–3.5) NS 2.0 (1.0–3.5) 2.0 (1.0–3.5) NS 2.0 (1.0–3.0) 2.5 (1.5–4.0) 0.0263
MSSSa 2.10 (0.78–5.24) 3.17 (1.16–5.87) 0.0415 1.97 (0.56–5.63) 2.33 (0.88–4.94) NS 2.28 (1.04–4.97) 4.32 (1.77–6.33) 0.0021
ARRa 0.40 (0.22–0.71) 0.43 (0.22–0.85) NS 0.40 (0.25–0.71) 0.42 (0.22–0.75) NS 0.37 (0.17–0.71) 0.48 (0.21–0.95) NS




58/129 (45.0) 135/200 (67.5) <0.0001 41/69 (59.4) 89/108 (82.4) 0.0007 17/60 (28.3) 46/92 (50.0) 0.008
The Mann–Whitney U test was used to compare continuous variables, and the chi-square test was used to compare categorical variables
















abnormalities compared with those in southern Japan
(p = 0.0105 and p = 0.0004). This suggests that higher
latitude increases the frequencies of Barkhof brain le-
sions and CSF IgG abnormalities independent of the
HLA-DRB1*04:05 allele. There were no significant dif-
ferences between northern and southern Japan in the
clinical features of MS patients with the DRB1*15:01
allele.
Multivariate regression analyses of factors contributing to
clinical features and laboratory findings
We adjusted for factors contributing to age at onset, namely
geographic region (northern vs. southern), sex, HLA-
DRB1*04:05, and HLA-DRB1*15:01. Only the DRB1*04:05
allele was significantly associated with an earlier age at dis-
ease onset (p < 0.0001) (Table 5). After adjusting for factors
contributing to MSSS, namely geographic region (northern
vs. southern), sex, age at onset, MS subtype, ARR, HLA-
DRB1*04:05, and HLA-DRB1*15:01, patients living at a
higher latitude and with the HLA-DRB1*04:05 allele were
independently associated with the lowest quartile of MSSS
(adjusted OR = 3.64, p < 0.0001 and adjusted OR = 1.81,
p = 0.0266, respectively). Older age at onset, SPMS, and
higher ARR were significantly associated with higher
MSSS (p = 0.0159, p < 0.0001, and p < 0.0001, respect-
ively). When the logistic regression model for benign
MS was used to adjust for the same confounding fac-
tors as MSSS, living at a higher latitude and carrying
the HLA-DRB1*04:05 allele were significantly associated
with benign MS (adjusted OR = 2.63, p = 0.0206; adjusted
OR = 2.49, p = 0.0275, respectively), while SPMS had a











27/65 (1:2.4) 25/55 (1:2.2) NS
Age (years)a 41 (34–49.5) 36 (28–49) NS
Age at onset (years)a 27 (21–34) 25 (20–36.8) NS
SPMS (%) 19/92 (20.7) 7/78 (9.0) 0.035
Disease duration (years)a 10 (6–17) 7.5 (4–14.8) NS
EDSSa 2.0 (1.0–3.5) 2.0 (1.0–3.0) NS
MSSSa 1.97 (0.56–5.63) 2.28 (1.04–4.97) NS
ARRa 0.40 (0.25–0.71) 0.37 (0.17–0.71) NS
Barkhof criteria (%) 69/92 (75.0 %) 44/78 (56.4 %) 0.0105
Positive OB and/or
increased IgG index (%)
41/69 (59.4 %) 17/60 (28.3 %) 0.0004
The Mann–Whitney U test was used to compare continuous variables, and the
chi-square test was used to compare categorical variables
ARR annualized relapse rate, EDSS Kurtzke’s Expanded Disability Status Scale,
MSSS Multiple Sclerosis Severity Score, OB oligoclonal IgG bands, SPMS
secondary progressive multiple sclerosis
aMedian (interquartile range)
Table 5 Multivariate analysis of factors contributing to clinical
and laboratory features
Age at disease onset β t value p value
Region (northern Japan) −0.0918 −1.94 NS
Sex (female) −0.0127 −0.27 NS
HLA-DRB1*04:05 allele (+) −0.1970 −4.12 <0.0001
HLA-DRB1*15:01 allele (+) −0.0239 −0.50 NS
MSSS (Q1/Q2–Q4) Adjusted OR 95 % CI p value
Region (northern Japan) 3.64 2.15–6.33 <0.0001
Sex (female) 0.98 0.55–1.76 NS
Age at onset 0.97 0.95–0.99 0.0159
SPMS 0.06 0.009–0.20 <0.0001
ARR 0.15 0.07 − 0.31 <0.0001
HLA-DRB1*04:05 allele (+) 1.81 1.07–3.07 0.0266
HLA-DRB1*15:01 allele (+) 1.46 0.83–2.56 NS
Benign MS Adjusted OR 95 % CI p value
Region (northern Japan) 2.63 1.18–6.09 0.0206
Sex (female) 0.87 0.37–2.00 NS
Age at onset 0.97 0.94–1.01 NS
SPMS 0.04 0.008–0.12 <0.0001
ARR 0.43 0.11–1.42 NS
HLA-DRB1*04:05 allele (+) 2.49 1.12–5.74 0.0275
HLA-DRB1*15:01 allele (+) 1.72 0.76–4.04 NS
Barkhof criteria Adjusted OR 95 % CI p value
Region (northern Japan) 1.63 1.01–2.63 0.0434
Sex (female) 0.80 0.46–1.35 NS
Age at onset 0.97 0.95–0.99 0.0132
SPMS 2.55 1.05–6.80 0.0384
Disease duration (years) 0.98 0.95–1.01 NS
ARR 1.05 0.67–1.74 NS
EDSS 0.98 0.85–1.13 NS
HLA-DRB1*04:05 allele (+) 0.49 0.30–0.80 0.0043
HLA-DRB1*15:01 allele (+) 1.45 0.85–2.53 NS
Positive OB and/or increased
IgG index
Adjusted OR 95 % CI p value
Region (northern Japan) 3.80 2.31–6.36 <0.0001
Sex (female) 1.36 0.78–2.36 NS
Age at onset 1.00 0.98–1.02 NS
SPMS 1.43 0.60–3.51 NS
ARR 0.99 0.66–1.49 NS
EDSS 1.00 0.87–1.16 NS
HLA-DRB1*04:05 allele (+) 0.39 0.23–0.65 0.0004
HLA-DRB1*15:01 allele (+) 1.65 0.95–2.88 NS
Benign MS was defined as an EDSS score≤ 2.0 at least 10 years after disease onset
ARR annualized relapse rate, CI confidence interval, EDSS Kurtzke’s Expanded
Disability Status Scale, MSSS Multiple Sclerosis Severity Score, NS not
significant, OB oligoclonal IgG bands, OR odds ratio, Q quartile, SPMS
secondary progressive multiple sclerosis
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negative association (p < 0.0001). Results from the multi-
variate regression analyses for MSSS and benign MS were
consistent with these results. Interestingly, MSSS was
estimated to decrease by 0.57 per DRB1*04:05 allele (p
= 0.0198, Fig. 1), suggesting a gene-dosage effect. A
younger age at onset also had a significant positive lin-
ear trend with dosage of DRB1*04:05 allele (p = 0.0027).
After adjusting for the geographic region (northern vs.
southern), sex, age at onset, MS subtype, disease
duration, ARR, EDSS, HLA-DRB1*04:05, and HLA-
DRB1*15:01, we observed a positive correlation be-
tween living at a higher latitude and the presence of
Barkhof brain lesions (adjusted OR = 1.63, p = 0.0434)
and a negative correlation between HL-DRB1*04:05 and
Barkhof brain lesions (adjusted OR = 0.49, p = 0.0043).
Additionally, a younger age at onset and SPMS were
positively associated with Barkhof brain lesions (p = 0.0132
and p = 0.0384, respectively). Living at a higher latitude also
had a strong positive association with positive OB and/or
increased IgG index (adjusted OR = 3.80, p < 0.0001).
DRB1*04:05 had a strong negative association with CSF
IgG abnormalities (and adjusted OR = 0.39, p = 0.0004, re-
spectively) after adjusting for geographic region (northern
to southern), sex, age at onset, MS subtype, ARR, EDSS,
HLA-DRB1*04:05, and HLA-DRB1*15:01.
Discussion
Using multivariate regression analyses, we found that liv-
ing at a higher latitude and carrying the DRB1*04:05 al-
lele independently lessened the severity of symptoms as
evaluated by MSSS. The analyses also revealed that
latitude significantly increases the emergence of two
hallmarks of MS: fulfillment of the Barkhof criteria for
MS, and CSF IgG abnormalities, and that DRB1*04:05
decreases the occurrence of these parameters. The
difference in clinical features between northern and
southern patients was not simply attributable to the
difference in the proportion of SPMS patients enrolled,
as even after excluding these patients, the difference
remained statistically significant.
Thus, DRB1*04:05 appears to decrease MSSS, the fre-
quency of brain lesions meeting the Barkhof criteria, and
CSF IgG abnormalities. This is in accordance with our pre-
vious report describing DRB1*04:05-positive MS to be a
mild disease with lower frequencies of Barkhof brain lesions
and CSF abnormalities [6]. DRB1*04 is also associated with
OB-negative MS in a Swedish population [27]. Worldwide,
the DRB1*04:05 allele is rare in the general population, but
it is one of the most common alleles in some select and iso-
lated populations, such as the Japanese, Sardinians, and
Papua New Guineans [28]. DRB1*04:05 is a common sus-
ceptibility allele for MS in the Japanese population, and
DR4 (DRB1*04:05-DQA1*05:01-DQB1*03:01) is also a sus-
ceptibility haplotype for MS in the Sardinian population
[29], both of which recently showed a steep rise in MS
prevalence [10, 30]. We reported that the proportion of
DRB1*04:05 carriers in MS patients rapidly increases with
descending year of birth [6]. Thus, DRB1*04:05 is a poten-
tial risk factor for MS in the younger generation, which is
growing up in a modernized environment. Surprisingly, in
our study, DRB1*04:05 had a gene-dosage effect on MSSS,
decreasing by 0.57 per DRB1*04:05 allele. Therefore,
DRB1*04:05 appears to be unique in its ability to both in-
crease susceptibility to MS and decrease its severity as de-
fined by MSSS. It would be of interest to test whether the
bidirectional effects of DRB1*04:05 are observed in other
populations, such as Sardinians, in which DRB1*04:05 is a
common susceptibility allele.
A higher latitude is known to increase MS risk, and this
is also true for the Japanese population [25]. It is notable
that among Japanese, latitude also has a strong influence on
clinical and laboratory manifestations, being positively asso-
ciated with fulfillment of the Barkhof criteria for MS and
CSF IgG abnormalities, but with less severity MS in pa-
tients living in northern Japan. In this study, we also found
no significant difference in DRB1 phenotypic frequency be-
tween northern and southern controls, suggesting that the
observed differences were not likely due to the underlying
genetic variation between northern and southern popula-
tions. It is interesting to note that latitude also exerts an
influence on clinical manifestations in the Japanese popula-
tion on the mainland with relatively homogeneous HLA
backgrounds [31]. In New Zealand, a weak inverse relation-
ship between latitude and disease severity has also been ob-
served [32]. Thus, environmental factors related to latitude
are assumed to be more important for producing differ-
ences in clinical features than HLA backgrounds.
The effects of latitude are bidirectional; it decreases
disease severity as defined by MSSS while increasing the
Fig. 1 Copy numbers of HLA-DRB1*04:05 allele and MSSS. MSSS is
estimated to significantly decrease by 0.57 per DRB1*04:05 allele
(p = 0.0198), with a possible linear dose effect
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frequencies of Barkhof brain lesions and CSF IgG abnor-
malities. These bidirectional effects, in part, mask the ef-
fects of DRB1*04:05 on MSSS and fulfillment of Barkhof
criteria for MS in northern MS patients. SPMS was associ-
ated with greater MSSS, but the frequency of SPMS was
smaller in the southern MS population than that in the
north. This suggests that the greater severity of MS in the
south is not related to a chronic progressive phase. After
excluding SPMS patients, greater MSSS scores in the
southern group than in the northern became more evident
in this study. Therefore, the greater MSSS scores in south-
ern MS patients might be related to neuroinflammation
during relapse, as well as poor recovery. Total brain T2-
weighted lesion load on MRI has little to no correlation
with MS disability [33, 34]. However, gray matter atrophy
and cortical lesion burdens are the most significant MRI
variables correlating with MS disability [35, 36]. In the fu-
ture, the measurement of brain parenchymal volume and
atrophy, as well as the assessment of cortical demyelination
using double-inversion recovery MRI images, are required
in our cohort to elucidate the factors influencing the differ-
ences in MS severity between the two areas. Although we
carefully excluded patients with longitudinally extensive
spinal cord lesions, spinal cord lesion load and spinal cord
atrophy should also be measured in the future. It is import-
ant to clarify the effects of latitude on these parameters.
The clinical features of MS in Asians have been re-
ported to be different to those in patients in Western
countries. In the fourth nationwide survey in Japan,
SPMS was observed in 15.2 % of patients with conven-
tional (classical)-type MS [10], suggesting that SPMS is
less common in Japanese patients than in Western pa-
tients. It has repeatedly been reported that Japanese pa-
tients with MS have low rates of CSF IgG abnormality
and Barkhof brain lesions [10, 21, 37]. Some studies have
reported that the presence of OB is associated with a
worse MS prognosis in Caucasians [38, 39], while others
found no significant difference in prognosis between
OB-positive and OB-negative MS patients, including a
Japanese cohort [27, 37, 40]. We found that neither the
presence of Barkhof brain lesions nor CSF abnormalities
was associated with MSSS, suggesting that these factors
may not be decisive prognostic factors for MS in Japanese
populations. We suggest that living at higher latitude
might independently exert stronger effects on MS severity
than CSF IgG abnormalities. Indeed, this hypothesis is
consistent with findings that higher latitude is associated
with milder disability in MS patients in New Zealand [32].
Further research is needed to elucidate other factors re-
lated to the association of latitude with MS severity in
Japanese populations.
In our study, the difference in disease severity in
northern patients, as shown by differences in MSSS be-
tween DRB1*04:05 carriers and non-carriers, is not as
prominent as in southern patients. In southern patients,
lower latitude and an absence of DRB1*04:05 increased
the median MSSS to 4.33 in the DRB1*04:05 non-
carriers. Conversely, in northern patients, higher latitude
and the presence of DRB1*04:05 decreased MSSS to 1.97
in DRB1*04:05 carriers. Because the latter value is close
to the lower limit, this lowering effect may not be obvi-
ous. Alternatively, the effects of latitude might be more
potent in DRB1*04:05 non-carriers than in DRB1*04:05
carriers. Further studies are needed to investigate the in-
teractions between the two factors in larger cohorts.
The DRB1*15:01 allele is a strong genetic risk factor for
MS in Caucasians and has been associated with earlier age
at onset [4] and OB positivity [41]. In the present study,
DRB1*15:01 was associated with CSF IgG abnormalities
and marginally correlated with fulfillment of the Barkhof
criteria for MS. However, these associations lost signifi-
cance after adjusting for contributing factors. Thus, the ef-
fects of DRB1*15:01 on clinical manifestations may be
smaller in Asian populations than in European populations.
We also found that DRB1*01:01, DRB1*09:01,
DRB1*13:02, and DRB1*15:02 were protective alleles
in the Japanese MS population. Based on a meta-analysis,
DRB1*09:01 has been reported to be a protective allele for
MS in a Chinese population, and this allele is more com-
mon in Asians than in other ethnic groups [42].
DRB1*01:01, DRB1*13:02, and DRB1*15:02 have been de-
termined to be novel protective alleles for MS in Japanese
populations by the present study. Among the Basque, a
Caucasian population living in northern Spain and
southwestern France, the DRB1*01:01 allele has a negative
association with the disease [43]. The DRB1*15:02-
DQB1*06:01 haplotype also decreases the risk for MS in a
Sardinian population [44]. Interestingly, DRB1*15:01 and
DRB1*15:02 only differ at amino acid position 86 (a valine
for DRB1*15:01 and a glycine for DRB1*15:02). The differ-
ence of only one amino acid results in opposite effects on
MS susceptibility. DRB1*15:01, which contains valine, only
tolerates small residues, while DRB1*15:02, which con-
tains glycine, can accommodate large aromatic peptide
residues [45]. This small difference may determine the
characteristic of presenting antigens, thereby resulting in
opposite effects on MS.
Our study has some limitations; first, we did not meas-
ure the effects of disease-modifying drugs (DMDs) on
clinical course. However, it would be difficult to explain
the differences in the clinical manifestations and disease
course according to regional and genetic factors based on
DMD usage alone as such factors could not be taken into
account in the use of DMDs in daily clinical practice. Sec-
ond, we could not study the interactions between HLA-
DRB1 and environmental risk factors because of the small
study sample size. The interaction between DRB1*15:01
and environmental risk factors, such as smoking, obesity,
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vitamin D, and Epstein–Barr virus infection, is well known
[46–48]; any interaction between DRB1*04:05 and these
environmental risk factors remains to be established.
Third, although this is the largest study comparing clinical
manifestations and genetic backgrounds between patients
residing in northern and southern Japan, the sample size
was still smaller than in Caucasian MS studies. Neverthe-
less, we believe it would be valuable to make further re-
gional comparisons of the clinical manifestations and
disease courses in genetically and culturally homogeneous
populations residing in a wide range of latitudes to shed
more light on the possible genetic and environmental in-
fluences on neuroinflammation.
Conclusions
Living at a higher latitude and carrying the DRB1*04:05 al-
lele reduces the severity of MS in Japanese MS populations
as defined by MSSS. However, both factors influence the
frequencies of Barkhof brain lesions and CSF IgG abnor-
malities in different ways; that is, higher latitudes increase
the frequencies of Barkhof brain lesions and CSF IgG ab-
normalities, whereas DRB1*04:05 decreases them. Further
large-scale studies focusing on genetic-environmental inter-
actions are needed to determine the factors associated with
the severity of neuroinflammation in MS.
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